DrugPatentWatch Database Preview
Details for Biologics License Application: 103792
Summary for BLA: 103792
| Tradename: | HERCEPTIN |
| Applicant: | Genentech |
| Ingredient: | trastuzumab |
| Patents: | 875 |
| Approval Date: | Sep 25, 1998 |
| Suppliers: see list | 1 |
Pharmacology for BLA: 103792
| Drug Class | HER2 Receptor Antagonist |
| Mechanism of Action | HER2/Neu/cerbB2 Antagonists |
US Patents for BLA: 103792
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | Novartis AG (Basel, CH) | 2039-02-26 | RX | Orphan | search |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | Array BioPharma Inc. (Boulder, CO) | 2028-10-22 | RX | Orphan | search |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | ACADEMIA SINICA (Taipei, TW) | 2034-05-27 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
